Aptose Biosciences to Present at Canaccord Genuity 39th Annual Growth Conference
SAN DIEGO and TORONTO, July 30, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief Executive Officer, and Gregory K. Chow, Executive Vice President and Chief Financial Officer and Jotin Marango, M.D., Ph.D., Senior Vice President and Chief Business Officer, will participate at the Canaccord Genuity 39th Annual Growth Conference being held from Wednesday, August 7th to Thursday, August 8th, 2019, at the Intercontinental Hotel, Boston, MA.
Dr. Rice will provide a corporate overview of the Company’s recent activities and strategic direction.
|Time:||12:00 p.m. ET|
|Date:||Thursday, August 8, 2018|
|Location:||Intercontinental Hotel, Boston, MA|
A live webcast of the Aptose presentation will be accessible by visiting the following link:
The webcast will be archived shortly after the live event and will be available for 90 days through the Aptose website at www.aptose.com.
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. APTO-253, the only known clinical stage agent that directly targets the MYC oncogene and inhibits its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk MDS. CG-806, an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor being developed to treat AML and certain B cell malignancies, is in a Phase 1 clinical trial for hematologic malignancies. For further information, please visit www.aptose.com.
For further information, please contact:
Executive Vice President, CFO
LifeSci Advisors, LLC
Released July 30, 2019